Evidence map›Paper›PMID 29507944›Full record

Trial reportJAMA neurology2018

Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial.

Iain D Croall, Daniel J Tozer, Barry Moynihan, Usman Khan, John T O'Brien, Robin G Morris, Victoria C Cambridge, Thomas R Barrick, Andrew M Blamire, Gary A Ford and 2 more

2 registry-linked trialsOpen access · hybridAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 52 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 11 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05169021 phase4not yet recruitingnot on this mapstarted 2021, after this paper: background citation

Folic Acid and Intensive Antihypertensive Therapy for Cerebrovascular and Cardiovascular Events Prevention Among Patients With Hypertension and Cerebral Small Vascular Diseases (FAITH)----A Multicenter, Randomized, Controlled, Open-label, 2x2 Factorial, Blinded End-point Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2021 to 2028Enrolled15,000ConditionsCerebral Small Vessel Diseases, StrokeArmsAmlodipine folic acid 5.8mg+intensive antihypertensive therapy, Amlodipine folic acid 5.8mg+standard antihypertensive therapy, Amlodipine+intensive antihypertensive therapy, Amlodipine+standard antihypertensive therapy
NCT05690997 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Intensive Blood Pressure Control on Cerebral Blood Flow and Cognition in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease

TypeinterventionalSponsorThe University of Hong KongRan2023 to 2025Enrolled104ConditionsSmall Vessel Cerebrovascular Disease, StrokeArmsIntensive treatment, Standard treatment
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 11 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Iain D CroallStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Daniel J TozerStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Barry MoynihanSt George's National Health Service Healthcare Trust, London, United Kingdom.
Usman KhanSt George's National Health Service Healthcare Trust, London, United Kingdom.
John T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
Robin G MorrisInstitute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
Victoria C CambridgeStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Thomas R BarrickMolecular and Clinical Sciences Research Institute, St George's, University of London, London, United Kingdom.
Andrew M BlamireMagnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Gary A FordOxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.
Hugh S MarkusStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
PRESERVE Study Team
University of Cambridge · GBNational Health Service · GBKing's College London · GBNewcastle University · GBSt George's, University of London · GB

Funding

British Heart Foundation TSA BHF 2010/01Department of HealthMedical Research Council MR/N026896/1
6 · The paper itself

Abstract

Importance: Blood pressure (BP) lowering is considered neuroprotective in patients with cerebral small vessel disease; however, more intensive regimens may increase cerebral hypoperfusion. This study examined the effect of standard vs intensive BP treatment on cerebral perfusion in patients with severe small vessel disease. Objective: To investigate whether standard vs intensive BP lowering over 3 months causes decreased cerebral perfusion in small vessel disease. Design, Setting, and Participants: This randomized clinical trial took place at 2 English university medical centers. Patients were randomized via a central online system (in a 1:1 ratio). Seventy patients with hypertension and with magnetic resonance imaging-confirmed symptomatic lacunar infarct and confluent white matter hyperintensities were recruited between February 29, 2012, and October 21, 2015, and randomized (36 in the standard group and 34 in the intensive group). Analyzable data were available in 62 patients, 33 in the standard group and 29 in the intensive group, for intent-to-treat analysis. This experiment examines the 3-month follow-up period. Interventions: Patients were randomized to standard (systolic, 130-140 mm Hg) or intensive (systolic, <125 mm Hg) BP targets, to be achieved through medication changes. Main Outcomes and Measures: Cerebral perfusion was measured using arterial spin labeling; the primary end point was change in global perfusion between baseline and 3 months, compared between treatment groups by analysis of variance. Linear regression compared change in perfusion against change in BP. Magnetic resonance imaging scan analysis was masked to treatment group. Results: Among 62 analyzable patients, the mean age was 69.3 years, and 60% (n = 37) were male. The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively. Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63). No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP. The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44). Conclusions and Relevance: Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease. Trial Registration: isrctn.org Identifier: ISRCTN37694103.

Indexed as

AgedAntihypertensive AgentsBlood PressureCerebrovascular CirculationDiffusion Tensor ImagingFemaleHumansHypertensionMaleMicrovesselsMiddle AgedTreatment OutcomeAntihypertensive Agents

Identifiers

PMID29507944
PMCPMC5885221
OpenAlexW2792254568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.